小血管炎患者入住ICU时急性呼吸衰竭的病因:一项多中心回顾性研究
该研究为法国10个ICU的回顾性多中心研究(2007年1月至2018年1月),纳入121例已知或新诊断小血管炎(Svv)合并急性呼吸衰竭(ARF)的患者,评估ARF的临床表现、主要病因及结局。免疫性病因67例(55%),非免疫性病因54例(45%),43%(n=52)存在多种病因并存;主要免疫性病因为弥漫性肺泡出血(DAH,n=47,39%),主要非免疫性病因为肺部感染(n=35,29%)。非免疫性ARF组90天和1年粗死亡率分别为32%和38%,高于免疫性组的15%和20%(均p=0.03),校正后Cox模型差异边缘显著(p=0.053)。在已知Svv的70例患者中,免疫抑制状态(OR 9.41,95%CI 1.52-58.3;p=0.016)和低血管炎活动度评分(OR 0.84,95%CI 0.77-0.93)与非免疫性病因独立相关。作者认为对以ARF起病或合并ARF的Svv患者须进行广泛的病因排查,识别非免疫性病因的预测因素有助于避免不必要的免疫抑制治疗。
要点
- Svv合并ARF患者中45%(54/121)为非免疫性病因,43%(52/121)存在多种病因并存,床旁须同时排查免疫与非免疫因素。
- 主要免疫性病因为DAH(39%,47/121),主要非免疫性病因为肺部感染(29%,35/121)。
- 非免疫性ARF组90天和1年粗死亡率分别为32%和38%,高于免疫性组的15%和20%(均p=0.03);校正后Cox模型p=0.053。
- 已知Svv患者中,免疫抑制状态(OR 9.41,95%CI 1.52-58.3;p=0.016)和低血管炎活动度评分(OR 0.84,95%CI 0.77-0.93)与非免疫性病因独立相关。
- 作者认为对以ARF起病或合并ARF的Svv患者须进行广泛的病因排查,识别非免疫性病因的预测因素有助于避免不必要的免疫抑制治疗。
适用人群与场景
- 2007年1月至2018年1月法国10个ICU收治的已知或新诊断小血管炎(Svv)合并急性呼吸衰竭(ARF)的成人患者,共121例,年龄中位数62(50-75)岁,男性62%。
研究设计与关键结果
- 研究类型:回顾性多中心研究,法国10个ICU,2007年1月至2018年1月,纳入121例Svv合并ARF患者。
- 人群基线:年龄中位数62(50-75)岁,男性62%,SAPSII中位数39(27-52),SOFA中位数6(4-8)。
- 病因分布:免疫性病因67例(55%),非免疫性病因54例(45%),43%(n=52)存在多种病因并存。
- 主要免疫性病因为弥漫性肺泡出血(DAH,n=47,39%),主要非免疫性病因为肺部感染(n=35,29%)。
- 非免疫性ARF组90天和1年粗死亡率分别为32%和38%,免疫性组分别为15%和20%(均p=0.03);校正后Cox模型p=0.053。
- 已知Svv患者(n=70)中,免疫抑制状态(OR 9.41,95%CI 1.52-58.3;p=0.016)和低血管炎活动度评分(OR 0.84,95%CI 0.77-0.93)与非免疫性病因独立相关,校正因素包括起病至ARF时间、呼吸症状至ICU入住时间及严重肾功能衰竭。
证据类型、等级与局限
- 证据类型:回顾性多中心研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为对以ARF起病或合并ARF的Svv患者须进行广泛的病因排查。
- 作者认为识别非免疫性病因的预测因素(免疫抑制状态、低血管炎活动度评分)有助于避免不必要的免疫抑制治疗。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
RATIONALE: Acute respiratory failure (ARF) in patients admitted to the intensive care unit (ICU) with known or de novo small-vessel vasculitis (Svv) may be secondary to the underlying immune disease or to other causes. Early identification of the cause of ARF is essential to initiate the most appropriate treatment in a timely fashion.
METHODS: A retrospective multicenter study in 10 French ICUs from January 2007 to January 2018 to assess the clinical presentation, main causes and outcome of ARF associated with Svv, and to identify variables associated with non-immune etiology of ARF in patients with known Svv.
RESULTS: During the study period, 121 patients [62 (50-75) years; 62% male; median SAPSII and SOFA scores 39 (27-52) and 6 (4-8), respectively] were analyzed. An immune cause was identified in 67 (55%), and a non-immune cause in 54 (45%) patients. ARF was associated with several causes in 43% (n = 52) of cases. The main immune cause was diffuse alveolar hemorrhage (DAH) (n = 47, 39%), whereas the main non-immune cause was pulmonary infection (n = 35, 29%). The crude 90-day and 1-year mortality were higher in patients with non-immune ARF, as compared with their counterparts (32% and 38% vs. 15% and 20%, respectively; both p = 0.03), but was marginally significantly higher after adjusted analysis in a Cox model (p = 0.053). Among patients with a known Svv (n = 70), immunosuppression [OR 9.41 (1.52-58.3); p = 0.016], and a low vasculitis activity score [0.84 (0.77-0.93)] were independently associated with a non-immune cause, after adjustment for the time from disease onset to ARF, time from respiratory symptoms to ICU admission, and severe renal failure.
CONCLUSIONS: An extensive diagnosis workup is mandatory in ARF revealing or complicating Svv. Non-immune causes are involved in 43% of cases, and their short and mid-term prognosis may be poorer than those of immune ARF. Readily identified predictive factors of a non-immune cause could help avoiding unnecessary immunosuppressive therapies.
参考来源
- Gibelin A, Dumas G, Valade S, et al. Causes of acute respiratory failure in patients with small-vessel vasculitis admitted to intensive care units: a multicenter retrospective study. Ann Intensive Care. 2021. PMID: 34817718. doi:10.1186/s13613-021-00946-x
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。